# US 2022/0064132 A1 · Leukotriene synthesis inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0064132 A1
- Document ID: US20220064132A1
- Status: Published application
- Kind: A1
- Application number: 17/420,885
- Filed: 2020-01-10
- Published: 2022-03-03
- Earliest claimed: 2019-01-11
- Assignees: Naegis Pharmaceuticals Inc.
- Applicants: Naegis Pharmaceuticals Inc.
- Inventors: David L. Burgoyne; Erin Debruin; Julia Fonarev; James Gee Ken Yee; John Michael Langlands
- Web page: https://patentgrep.com/patent/US20220064132A1

## CPC

- C07D 215/14: Radicals substituted by oxygen atoms
- C07D 277/68: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Provided are specific leukotriene synthesis inhibitor compounds and pharmaceutical compositions comprising the compounds and methods of using the compounds and the pharmaceutical compositions in treating, for example, inflammatory diseases or conditions.

## Claims

### Claim 1

A compound of formula (1)
or a pharmaceutically acceptable enantiomer, diastereomer, salt, or solvate thereof, wherein:
Ar is unsubstituted or is substituted with one or two substituents selected from halide, C1-6alkyl; —S—C1-6alkyl; —O—C1-6alkyl; and —SO2—C1-6alkyl;
L is selected from a direct bond and —CH2— (methylene);
R1 is selected from hydrogen, halide, C1-C6alkyl, C1-C6haloalkyl and C1-C6alkoxy;
A is selected from a direct bond, —CH2— and —CH2CH2—;
E is selected from —C(O)—R2, C(OR3)R4R5 and CH(R6)NR7R8;
R2 is selected from methyl, ethyl and phenyl;
R3 is H;
R4 is selected from hydrogen, C1-C7alkyl and phenyl;
R5 is selected from C1-C7alkyl, C1-C7haloalkyl, phenyl and halophenyl;
R6 is selected from hydrogen, methyl, halogenated methyl and ethyl; and
R7 is hydrogen and R8 is hydrogen, methyl or ethyl; or R7 and R8 together form a 5- or 6-membered heterocycle which is optionally substituted with a substituent selected from C1-C6alkyl and carboxylic acid.

### Claim 2 (depends on 1)

The compound of claim 1 wherein Ar is unsubstituted.

### Claim 3 (depends on 1)

The compound of claim 1 wherein Ar is substituted with a single substituent.

### Claim 4 (depends on 1)

The compound of claim 1 wherein Ar is substituted with a single substituent which is —S—CH3.

### Claim 5 (depends on 1)

The compound of claim 1 wherein L is a direct bond.

### Claim 6 (depends on 1)

The compound of claim 1 wherein L is methylene.

### Claim 7 (depends on 1)

The compound of claim 1 wherein R1 is hydrogen or C1-C6alkoxy.

### Claim 8 (depends on 1)

The compound of claim 1 wherein A is a direct bond.

### Claim 9 (depends on 1)

The compound of claim 1 wherein A is —CH2CH2—.

### Claim 10 (depends on 1)

The compound of claim 1 wherein E is —C(OR3)R4R5 where R3 is H, R4 is C1-C2alkyl, and R5 is trifluoromethyl.

### Claim 11 (depends on 1)

The compound of claim 1 as a pure enantiomer or as a non-racemic mixture of enantiomers of compounds of formula (1).

### Claim 12 (depends on 1)

The compound of claim 1 selected from:
1-[4-(1,3-benzothiazol-2-yloxy)-3-methoxyphenyl]-3-(trifluoromethyl)pentan-3-ol;
1-{3-methoxy-4-[(4-methylsulfanyl-1,3-benzothiazol-2-yl)oxy]phenyl}-3-(trifluoromethyl)pentan-3-ol;
1-{4-[(4,6-difluoro-1,3-benzothiazol-2-yl)oxy]-3-methoxyphenyl}-3-(trifluoromethyl)pentan-3-ol;
1-{4-[(6-fluoro-1,3-benzothiazol-2-yl)oxy]-3-methoxyphenyl}-3-(trifluoromethyl)pentan-3-ol;
4-[4-(1,3-benzothiazol-2-yloxy)-3-methoxyphenyl]-1,1,1-trifluoro-2-methylbutan-2-ol;
1,1,1-trifluoro-4-(3-methoxy-4-{[4-(methylsulfanyl)-1,3-benzothiazol-2-yl]oxy}phenyl)-2-methylbutan-2-ol;
1-(3-methoxy-4-{[4-(methylsulfanyl)-1,3-benzothiazol-2-yl]oxy}phenyl)pentan-3-ol; and
1-(4-{[4-(methylsulfanyl)-1,3-benzothiazol-2-yl]oxy}phenyl)-3-(trifluoromethyl)pentan-3-ol.

### Claim 13 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable enantiomer, salt or solvate thereof, and at least one pharmaceutically acceptable carrier, diluent, excipient and/or adjuvant.

### Claim 14 (depends on 13)

The pharmaceutical composition of claim 13 in the form of an eyedrop.

### Claim 15 (depends on 1)

A method of treating an inflammatory disease or inflammatory condition comprising administrating to a subject in need thereof an effective amount of a compound of claim 1.

### Claim 16 (depends on 15)

The method of claim 15 for treating an ocular inflammatory disease or an ocular inflammatory condition.

### Claim 17 (depends on 1)

A method of treating a respiratory disease or condition comprising administering to a subject in need thereof a therapeutically-effective amount of a compound of claim 1.

### Claim 18 (depends on 1)

A method of treating a neurodegenerative disease, condition or disorder comprising administering to a subject in need thereof a therapeutically-effective amount of a compound of claim 1.

### Claim 19

A compound of formula (1)
or a pharmaceutically acceptable enantiomer, diastereomer, salt, or solvate thereof, wherein:
Ar is a 9- or 10-membered bicyclic aromatic ring system, where Ar is optionally substituted with one, two or three substituents;
L is selected from a direct bond and methylene;
R1 is selected from hydrogen, halide, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, C3-C6cycloalkoxy and C1-C6alkoxy substituted with C3-C6cycloalkyl;
A is selected from a direct bond, —CH2— and —CH2CH2—;
E is selected from —C(O)—R2, C(OR3)R4R5 and CH(R6)NR7R8;
R2 is selected from methyl, ethyl and phenyl;
R3 is selected from H, alkyl and substituted alkyl;
R4 is selected from hydrogen, alkyl and phenyl;
R5 is selected from C1-C7alkyl, C1-C7haloalkyl, phenyl and substituted phenyl;
R6 is selected from hydrogen, methyl, halogenated methyl and ethyl;
R7 is hydrogen; and R8 is hydrogen, methyl or ethyl; with the proviso that together, R7 and R8 may form a 5 or 6-membered, optionally substituted, heterocycle.

### Claim 20 (depends on 19)

A pharmaceutical composition comprising a compound according to claim 19, or a pharmaceutically acceptable enantiomer, salt or solvate thereof, and at least one pharmaceutically acceptable carrier, diluent, excipient and/or adjuvant.

### Claim at position 21

-102. (canceled)
